Lemborexant

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Renal Impairment

Conditions

Renal Impairment

Trial Timeline

Feb 7, 2018 → Aug 24, 2018

NCT ID

NCT03443063

About Lemborexant

Lemborexant is a phase 1 stage product being developed by Eisai for Renal Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT03443063. Target conditions include Renal Impairment.

What happened to similar drugs?

20 of 20 similar drugs in Renal Impairment were approved

Approved (20) Terminated (0) Active (0)

✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved

✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved

✅Tacrolimus, Prograf®Astellas PharmaApproved

✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved

✅Tacrolimus + CyclosporineAstellas PharmaApproved

✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05594589	Phase 2	Completed	Nov 30, 2022	May 24, 2024	Sleep Initiation and Maintenance Disorders
NCT04890561	Phase 1	Completed	May 17, 2021	Aug 12, 2021	Healthy Volunteers
NCT04555733	Phase 1	Completed	Oct 26, 2020	Jan 13, 2021	Healthy Volunteer
NCT04573556	Pre-clinical	Completed	Oct 17, 2020	Mar 17, 2022	Sleep Initiation and Maintenance Disorders
NCT03443063	Phase 1	Completed	Feb 7, 2018	Aug 24, 2018	Renal Impairment
NCT03440424	Phase 1	Completed	Jan 26, 2018	Apr 23, 2018	Hepatic Impairment

Competing Products

20 competing products in Renal Impairment

See all competitors

Product	Company	Stage	Hype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109	MBX Biosciences	Phase 1	23
LY3473329	Eli Lilly	Phase 1	29
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
SPR001	Spruce Biosciences	Phase 2	25
SPR001	Spruce Biosciences	Phase 2	25
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
Tildacerfont	Spruce Biosciences	Phase 2	17
Drotrecogin alfa activated (Xigris)	Eli Lilly	Phase 2	35
LY3819469	Eli Lilly	Phase 1	29
Atezolizumab + Cabozantinib	Chugai Pharmaceutical	Phase 3	32
DS-6000a + DS-6000a	Daiichi Sankyo	Phase 1	33
DS-1093a	Daiichi Sankyo	Phase 1	29
CS-3150	Daiichi Sankyo	Phase 3	40
AGS-16C3F	Astellas Pharma	Phase 1	29
AGS-16M8F	Astellas Pharma	Phase 1	29
CP-461	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
YM178	Astellas Pharma	Phase 1	29
intravenous immunoglobulins (IVIG)	Astellas Pharma	Phase 1	29
bixalomer	Astellas Pharma	Pre-clinical	26